JP2022550297A5 - - Google Patents
Info
- Publication number
- JP2022550297A5 JP2022550297A5 JP2022518675A JP2022518675A JP2022550297A5 JP 2022550297 A5 JP2022550297 A5 JP 2022550297A5 JP 2022518675 A JP2022518675 A JP 2022518675A JP 2022518675 A JP2022518675 A JP 2022518675A JP 2022550297 A5 JP2022550297 A5 JP 2022550297A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- acceptable salt
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905532P | 2019-09-25 | 2019-09-25 | |
| US62/905,532 | 2019-09-25 | ||
| US202063021216P | 2020-05-07 | 2020-05-07 | |
| US63/021,216 | 2020-05-07 | ||
| US202063069831P | 2020-08-25 | 2020-08-25 | |
| US63/069,831 | 2020-08-25 | ||
| PCT/IB2020/058854 WO2021059136A1 (en) | 2019-09-25 | 2020-09-22 | Polyheterocyclic modulators of sting (stimulator of interferon genes) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550297A JP2022550297A (ja) | 2022-12-01 |
| JP2022550297A5 true JP2022550297A5 (https=) | 2023-09-25 |
Family
ID=72744805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518675A Ceased JP2022550297A (ja) | 2019-09-25 | 2020-09-22 | Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のヘテロ多環式モジュレーター |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12297190B2 (https=) |
| EP (1) | EP4034534A1 (https=) |
| JP (1) | JP2022550297A (https=) |
| KR (1) | KR20220070254A (https=) |
| CN (1) | CN114728946A (https=) |
| AU (1) | AU2020355343B2 (https=) |
| BR (1) | BR112022005463A2 (https=) |
| CA (1) | CA3155569A1 (https=) |
| CL (1) | CL2022000736A1 (https=) |
| CO (1) | CO2022003321A2 (https=) |
| CR (1) | CR20220126A (https=) |
| DO (1) | DOP2022000066A (https=) |
| EC (1) | ECSP22022958A (https=) |
| GE (2) | GEAP202315908A (https=) |
| IL (1) | IL291650A (https=) |
| MX (1) | MX2022003633A (https=) |
| PE (1) | PE20221784A1 (https=) |
| PH (1) | PH12022550709A1 (https=) |
| PY (1) | PY2058444A (https=) |
| TW (2) | TWI757889B (https=) |
| UY (1) | UY38892A (https=) |
| WO (1) | WO2021059136A1 (https=) |
| ZA (1) | ZA202203412B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022063205A1 (zh) * | 2020-09-24 | 2022-03-31 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
| CN117321055A (zh) * | 2021-03-18 | 2023-12-29 | 辉瑞公司 | Sting(干扰素基因刺激剂)的调节剂 |
| US11964978B2 (en) | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
| US12065427B2 (en) * | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| CN119212989A (zh) * | 2022-05-18 | 2024-12-27 | 豪夫迈·罗氏有限公司 | 作为sting激动剂的吡唑衍生物 |
| JP2024041730A (ja) * | 2022-09-14 | 2024-03-27 | ファイザー・インク | Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のモジュレーター |
| CA3266173A1 (en) * | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| CN117045647A (zh) * | 2023-08-03 | 2023-11-14 | 浙江大学 | 4-羟基吡唑类化合物及其衍生物和盐在制备抑制铁死亡药物中的应用 |
| WO2025228900A1 (en) * | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| WO2025228889A1 (en) * | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
| US20250333414A1 (en) * | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228899A1 (en) * | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
| US20250333398A1 (en) * | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228902A1 (en) * | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP2432776B1 (en) | 2009-05-21 | 2019-09-11 | Universite Laval | Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CA2955184A1 (en) | 2016-01-25 | 2017-07-25 | Pfizer Inc. | Combination of an ox40 agonist and a 4-1bb agonist for treating cancer |
| JP2019510802A (ja) * | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| UA125730C2 (uk) | 2017-06-22 | 2022-05-25 | Курадев Фарма Лімітед | Низькомолекулярні модулятори sting людини |
| WO2019002606A1 (en) * | 2017-06-30 | 2019-01-03 | Selvita S.A. | ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS |
| MX2020008265A (es) * | 2018-02-16 | 2020-09-21 | UCB Biopharma SRL | Derivados farmaceuticos del anillo heterobiciclico 6,5. |
| US10538542B2 (en) | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
| US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
| MX2021010701A (es) | 2019-03-05 | 2022-02-21 | F Star Therapeutics Inc | Compuestos, composiciones y metodos para el tratamiento de enfermedad. |
| US20220227761A1 (en) | 2019-05-16 | 2022-07-21 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
-
2020
- 2020-09-22 KR KR1020227013541A patent/KR20220070254A/ko active Pending
- 2020-09-22 EP EP20786063.6A patent/EP4034534A1/en active Pending
- 2020-09-22 MX MX2022003633A patent/MX2022003633A/es unknown
- 2020-09-22 PE PE2022000465A patent/PE20221784A1/es unknown
- 2020-09-22 WO PCT/IB2020/058854 patent/WO2021059136A1/en not_active Ceased
- 2020-09-22 PH PH1/2022/550709A patent/PH12022550709A1/en unknown
- 2020-09-22 GE GEAP202315908A patent/GEAP202315908A/en unknown
- 2020-09-22 CN CN202080081716.2A patent/CN114728946A/zh active Pending
- 2020-09-22 AU AU2020355343A patent/AU2020355343B2/en active Active
- 2020-09-22 JP JP2022518675A patent/JP2022550297A/ja not_active Ceased
- 2020-09-22 BR BR112022005463A patent/BR112022005463A2/pt unknown
- 2020-09-22 CA CA3155569A patent/CA3155569A1/en active Pending
- 2020-09-22 CR CR20220126A patent/CR20220126A/es unknown
- 2020-09-22 GE GEAP202015908A patent/GEP20237572B/en unknown
- 2020-09-23 UY UY0001038892A patent/UY38892A/es not_active Application Discontinuation
- 2020-09-23 US US17/029,557 patent/US12297190B2/en active Active
- 2020-09-24 TW TW109133180A patent/TWI757889B/zh active
- 2020-09-24 TW TW111103766A patent/TW202244043A/zh unknown
- 2020-09-25 PY PY202002058444A patent/PY2058444A/es unknown
-
2022
- 2022-03-23 ZA ZA2022/03412A patent/ZA202203412B/en unknown
- 2022-03-23 IL IL291650A patent/IL291650A/en unknown
- 2022-03-23 CO CONC2022/0003321A patent/CO2022003321A2/es unknown
- 2022-03-24 EC ECSENADI202222958A patent/ECSP22022958A/es unknown
- 2022-03-24 CL CL2022000736A patent/CL2022000736A1/es unknown
- 2022-03-25 DO DO2022000066A patent/DOP2022000066A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022550297A5 (https=) | ||
| JP7085635B2 (ja) | Ｂｃｌ－２阻害剤又はＢｃｌ－２／Ｂｃｌ－ｘＬ二重阻害剤及びＢＴＫ阻害剤の組合せ製品並びに疾患の予防及び／又は治療におけるその使用 | |
| Chen et al. | Design, synthesis, and biological evaluation of stable colchicine-binding site tubulin inhibitors 6-aryl-2-benzoyl-pyridines as potential anticancer agents | |
| Li et al. | Discovery, synthesis, and evaluation of highly selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor for the potential treatment of metastatic triple-negative breast cancer | |
| AU2011240003A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| Zhang et al. | Design and syntheses of permethyl ningalin B analogues: potent multidrug resistance (MDR) reversal agents of cancer cells | |
| UA119537C2 (uk) | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ | |
| US20140213575A1 (en) | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines | |
| JP2023538018A (ja) | ネトーシスの処置及び／又は予防における使用のための方法及び化合物 | |
| JP2024533975A (ja) | Ｐｉ３ｋアイソフォームアルファを阻害する化合物及びがんを処置するための方法 | |
| US10646464B2 (en) | Methods for treating cancer | |
| CN101222850B (zh) | 治疗对药物有抗性的癌症的方法 | |
| AU2010235917A1 (en) | Combination of organic compounds | |
| WO2022247881A1 (zh) | 治疗肿瘤的联合疗法 | |
| RU2754131C1 (ru) | Комбинированная терапия ингибитором ezh2 | |
| US8183285B2 (en) | Therapeutic agent for irritable bowel syndrome and methods thereof | |
| CN117545480A (zh) | 作为赖氨酰氧化酶的抑制剂的双噻唑衍生物 | |
| TW202547488A (zh) | 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合 | |
| WO2014058785A1 (en) | Combination therapy | |
| HK40091747A (zh) | 用於治疗癌症的组合疗法 |